Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2025-07-22 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
ASTRAZENECA PLANS TO INVEST $50BN IN THE US
Foreign Filer Report
2025-07-22 English
AstraZeneca plans to invest $50bn in the US
Regulatory Filings Classification · 1% confidence The document is clearly identified as originating from 'RNS Number : 9506R' and contains standard boilerplate language from 'RNS, the news service of the London Stock Exchange.' RNS filings are general regulatory announcements. The content details a major strategic investment plan ($50 billion) in US manufacturing and R&D, which is a significant corporate announcement but does not fit the specific definitions for 10-K (Annual Report), ER (Earnings Release), IR (Interim Report), or CAP (Capital/Financing Update, as this is an investment plan, not a specific fundraising event). Since it is a broad, material corporate announcement distributed via the official regulatory news service (RNS), and it doesn't fit a more specific category like DIRS, DIV, or M&A, the most appropriate classification is the general regulatory announcement category.
2025-07-22 English
UPDATE ON ANSELAMIMAB IN AL AMYLOIDOSIS
Foreign Filer Report
2025-07-16 English
Update on anselamimab in AL amyloidosis
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 1999R' and contains a date stamp typical of regulatory news services. The content is an 'Update on CARES Phase III clinical programme' providing high-level results of a clinical trial, including quotes from executives and investigators, and concluding with notes and contact information typical of a formal announcement distributed via a regulatory news service. The presence of 'RNS Number' and the structure strongly indicate this is a regulatory announcement, not a full financial report (like 10-K or IR) or a presentation (IP). Since it is a general regulatory announcement that doesn't fit perfectly into the other specific categories (like DIRS, DIV, or MANG), the most appropriate classification is the general regulatory filing category.
2025-07-16 English
BAXDROSTAT MET PRIMARY ENDPT IN BAXHTN PHIII TRIAL
Foreign Filer Report
2025-07-14 English
Baxdrostat met primary endpt in BaxHTN PhIII trial
Earnings Release Classification · 1% confidence The document is identified by the 'RNS Number : 9001Q' and contains a date stamp (14 July 2025) followed by an announcement of clinical trial results ('Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial'). It explicitly states, 'This announcement contains inside information' and concludes with regulatory boilerplate language indicating submission through RNS, the news service of the London Stock Exchange, approved as a Primary Information Provider. This structure is characteristic of a general regulatory news service announcement, which fits the definition of 'Regulatory Filings' (RNS) as a broad category for official, time-sensitive disclosures that aren't specifically a 10-K, ER, or DEF 14A. Since it is an announcement of results rather than the full financial report (10-K or IR), and it is not a specific management change (MANG) or dividend notice (DIV), RNS is the most appropriate classification. Q2 2025
2025-07-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.